IDiyas

For the Inventor, By the Inventor

Scotch Plains, NJ, United States of America

James V Heck

USPTO Granted Patents = 32 

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 265(Granted Patents)


Location History:

  • Fanwood, NJ (US) (1983 - 1992)
  • Scotch Plains, NJ (US) (1989 - 2002)

Company Filing History:

goldMedal32 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1983-2002

Loading Chart...
32 patents (USPTO):
1. 6399640 - Arylthiazolidinedione and aryloxazolidinedione derivatives (2002-06-04),
2. 5985844 - Homoerythromycin A derivatives modified at the 4'-and 8A-positions (1999-11-16),
3. 5541177 - 3-aryl or heteroaryl-7-heteroaralkylamido cephalosporin compounds, (1996-07-30),
4. 5534507 - 3-aryl or heteroaryl-7-heteroaralkylamido cephalosporin compounds, (1996-07-09),
5. 5455239 - 3-aryl of heteroaryl-7-heteroaralkylamido cephalosporin compounds, (1995-10-03),
6. 5382575 - (N-pyridiniumphenyl)-carbapenems (1995-01-17),
7. 5356889 - 2-(9-fluorenonyl)-carbapenem intermediates (1994-10-18),
8. 5350746 - Triazolyl and tetrazolyl phenyl substituted carbapenems, compositions (1994-09-27),
9. 5276149 - 2-(N-imidazoliumphenyl)-carbapenems (1994-01-04),
10. 5229363 - Cyclic hexapeptide compounds (1993-07-20),
11. 5192758 - 2-biphenyl-carbapenem antibacterial agents (1993-03-09),
12. 5144028 - 2-(9-fluorenonyl)-carbapenem intermediates (1992-09-01),
13. 5137884 - N-tetrazolyl beta-lactams (1992-08-11),
14. 5120729 - Beta-lactams as antihypercholesterolemics (1992-06-09),
15. 5034384 - 2-(9-fluorenonyl)-carbapenem antibacterial agents (1991-07-23),

Title: Innovations and Contributions of James V. Heck in Pharmaceutical Patents

Introduction

James V. Heck, based in Scotch Plains, NJ, is a prominent inventor with an impressive portfolio of 32 patents. His work primarily focuses on innovative pharmaceutical compounds, particularly in the fields of diabetes treatment and antibiotic development.

Latest Patents

Among his latest inventions are the Arylthiazolidinedione and aryloxazolidinedione derivatives. These compounds, which include substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones, demonstrate potent agonist properties of PPAR. They hold substantial potential for treating various health conditions such as diabetes, hyperglycemia, hyperlipidemia, atherosclerosis, obesity, and vascular restenosis, along with other PPAR mediated diseases. Additionally, his research includes Homoerythromycin A derivatives that are modified at the 4'- and 8A-positions. These compounds serve as macrolide antibiotics and are valuable as intermediates in creating additional macrolide antibiotics. The related pharmaceutical compositions and their methods of use further illustrate the significance of his work.

Career Highlights

James V. Heck is affiliated with Merck & Company, Inc., a leader in pharmaceuticals. His contributions to the company have significantly advanced the field of medicine through innovative patentable inventions that pave the way for effective treatment options in various therapeutic areas.

Collaborations

Throughout his career, James has worked alongside esteemed colleagues, including Burton G. Christensen and Lovji D. Cama, fostering a collaborative environment that combines expertise to yield novel solutions in pharmaceutical sciences.

Conclusion

James V. Heck's work continues to impact the pharmaceutical industry profoundly. With a track record of significant patents and collaborations, his innovative spirit elevates the standards of drug development, offering hope for various medical conditions through his groundbreaking inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…